2008-07-03 03:29:17 -
www.companiesandmarkets.com adds new report - Nabi Biopharmaceuticals - SWOT Analysis www.companiesandmarkets.com/Summary-Company-Profile/Nabi-Biophar ..
Nabi Biopharmaceuticals - SWOT Analysis Company Profile is the essential source for top-level company data and information. The report examines the companys key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.
Nabi Biopharmaceuticals (Nabi) develops and markets products that target serious medical conditions in the areas of transplantation, infectious disease,
nicotine addiction, and hematology/oncology. The company markets Nabi-HB for postexposure prevention of hepatitis B infection and Aloprim for the treatment of chemotherapy-induced hyperuricemia. Nabi is headquartered in Boca Raton, Florida and employs about 650 people. The company recorded revenues of $89.8 million during the fiscal year ended December 2006, a decrease of 4.4% over 2005. The operating loss of the company was $54.2 million during fiscal year 2006, as compared to the operating loss of $109.2 million in 2005. The net loss in fiscal year 2006 was $58.7 million, as compared to the net loss of $128.4 million in 2005.
Scope of the Report
- Provides all the crucial company information required for business and competitor intelligence needs
- Contains a study of the major internal and external factors affecting the company in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams
- Data is supplemented with details on the companys history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement
Reasons to Purchase
- Support sales activities by understanding your customers businesses better
- Qualify prospective partners and suppliers
- Keep fully up to date on your competitors business structure, strategy and prospects
- Obtain the most up to date company information available
